166 related articles for article (PubMed ID: 17940134)
1. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein.
Morimoto K; Nakakariya M; Shirasaka Y; Kakinuma C; Fujita T; Tamai I; Ogihara T
Drug Metab Dispos; 2008 Jan; 36(1):6-9. PubMed ID: 17940134
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Shaik N; Giri N; Pan G; Elmquist WF
Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
Ito M; Kusuhara H; Ose A; Kondo T; Tanabe K; Nakayama H; Horita S; Fujita T; Sugiyama Y
AAPS J; 2017 Jan; 19(1):286-297. PubMed ID: 27800573
[TBL] [Abstract][Full Text] [Related]
6. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.
Jonker JW; Wagenaar E; van Deemter L; Gottschlich R; Bender HM; Dasenbrock J; Schinkel AH
Br J Pharmacol; 1999 May; 127(1):43-50. PubMed ID: 10369454
[TBL] [Abstract][Full Text] [Related]
7. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
8. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4).
Ose A; Ito M; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Hosokawa M; Schuetz JD; Sugiyama Y
Drug Metab Dispos; 2009 Feb; 37(2):315-21. PubMed ID: 19029202
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
10. Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
Morimoto K; Nagami T; Matsumoto N; Wada S; Kano T; Kakinuma C; Ogihara T
J Toxicol Sci; 2012; 37(6):1217-23. PubMed ID: 23208436
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice.
Hatori A; Arai T; Yanamoto K; Yamasaki T; Kawamura K; Yui J; Konno F; Nakao R; Suzuki K; Zhang MR
Nucl Med Biol; 2009 Jan; 36(1):47-55. PubMed ID: 19181268
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
14. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
15. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Miller DW; Hinton M; Chen F
Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
[TBL] [Abstract][Full Text] [Related]
17. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
[TBL] [Abstract][Full Text] [Related]
18. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
[TBL] [Abstract][Full Text] [Related]
19. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
20. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]